Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single ascending dose study of ABP-700 in healthy volunteers
NL-OMON25748Phase 1Unknown
- Sponsor
- Annovation Biopharma
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind trial of moxetomidate (3 arms), sponsored by Annovation Biopharma. Primary endpoints: Safety and tolerability of single ascending IV infusion doses of ABP-700 and Maximum tolerated dose. Status: unknown.
02
Drugs
moxetomidate
Beyond the preview
Go deeper on NL-OMON25748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25748.